BELLUS Health Inc.
Pagina dedicata companiei BELLUS Health Inc. listata cu simbolul US.BLU
Descriere companie[edit | ]
BELLUS Health Inc. (www.bellushealth.com) is a clinical stage pharmaceutical company that is focused on developing a P2X3 antagonist to address various afferent hypersensitization-related disorders. The Company’s lead candidate, BLU-5937, is being studied in Phase II clinical trials in refractory chronic cough and chronic pruritus associated with atopic dermatitis. It is developing BLU-5937 for the treatment of chronic cough and chronic pruritus, or chronic itch. The Company is focused on SOOTHE, which is in a Phase IIb trial of BLU-5937 in refractory chronic cough patients. It is also focused on BLUEPRINT, which is in a Phase II trial in chronic pruritus associated with atopic dermatitis. The RELIEF trial established proof-of-concept for BLU-5937 in the treatment of RCC patients.
Grafic actiuni companie[edit | ]